PROGRAM CHAIR
Diwakar Davar, MD
Assistant Professor of Medicine
University of Pittsburgh
Department of Medicine
Hematology/Oncology
Pittsburgh, PA
FACULTY
Shayma Master Kazmi, M.D., R.Ph
Medical Lead of Advanced Oncology, Oncology/Hematology
Comprehensive Care and Research Center
Philadelphia, PA
PROGRAM OVERVIEW
This online activity is focused on the identification and exploration of immune-related adverse events, their management, and the critical role of emergency department physicians in the care of patients treated with immune checkpoint inhibitors.
TARGET AUDIENCE
Emergency department physicians and other healthcare professionals working as part of a multidisciplinary care team that sees oncology patients with immune-related adverse events.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Discuss the effects of immune checkpoint inhibitor (ICI) therapy on immune system cells that lead to immune-related adverse events (IrAEs) in patients with cancer seen by emergency physicians;
- Describe the role of emergency physicians in the recognition of signs and symptoms of ICI IrAEs and their management in patients with cancer; and
- Review strategies to overcome barriers to the implementation of necessary practice changes for emergency physicians seeing cancer patients with ICI IrAEs.
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the emergency care of cancer patients with ICI IrAEs. Credits: 1.0 ANCC Contact Hour.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Davar is a consultant and conducts research for Merck, BMS, Tesaro, and Checkmate Pharmaceuticals.
Dr. Kazmi is a consultant and serves on Speakers Bureaus for Lilly, Merck, Eisai, Takeda, and Immonomedics.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit, participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the online activity; and
3. Submit the evaluation form to Med Learning Group.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: February 10, 2020
EXPIRATION DATE: February 10, 2021
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
